Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Nishinomiya, Hyogo, Japan Clinical Trials

A listing of Nishinomiya, Hyogo, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (4) clinical trials

A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B

This study will examine the long-term safety and efficacy of rIX-FP for the control and prevention of bleeding episodes in children and adults with severe hemophilia B. The study will include subjects who have not previously been treated with Factor IX products, subjects who previously completed a CSL-sponsored rIX-FP lead-in ...

Phase

0.0 miles

Learn More »

A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis

Study duration per participant is approximately 13 months including 6-Month factor or BPA prophylaxis period and 7-Month fitusiran treatment period. Study duration for patients in the subgroup of Cohort A is approximately 7 months corresponding to a 7-Month fitusiran treatment period. Participants completing the treatment period will be proposed to ...

Phase

0.0 miles

Learn More »

Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

This study is a randomized, double-blind, placebo-controlled, 72-week study followed by a 72-week open-label period. The purpose is to characterize the long-term effects of ataluren-mediated dystrophin restoration on disease progression. Participants will be randomized in a 1:1 ratio to ataluren or placebo. Participants will receive blinded study drug three times ...

Phase

2.53 miles

Learn More »

A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer

This study is an international phase 3 randomized, open-label, parallel group efficacy and safety study to evaluate oral daily relugolix 120 mg in patients with androgen-sensitive advanced prostate cancer who require at least 1 year (48 weeks) of continuous androgen deprivation therapy. Relugolix 120 mg orally once daily or leuprolide ...

Phase

9.61 miles

Learn More »